Journal of Digestive Cancer Research

  • 제4권1호
  • /
  • Pages.32-35
  • /
  • 2016
  • /
  • 2950-9394(pISSN)
  • /
  • 2950-9505(eISSN)
대한소화기암연구학회 (Korean Society of Gastrointestinal Cancer Research)
권호 표지

수술과 항암치료 후 종양표지자 검사의 상승으로 복막 가성점액종의 재발을 확인한 1례

A Case of Recurred Pseudomyxoma Peritonei Identified by Serially Elevated Serum CEA Levels after Cytoreductive Surgery and Intraperitoneal Chemotherapy

  • 한인섭 (부산대학교 의과대학 내과학교실) ;
  • 송근암 (부산대학교 의과대학 내과학교실) ;
  • 김광하 (부산대학교 의과대학 내과학교실) ;
  • 이봉은 (부산대학교 의과대학 내과학교실) ;
  • 백동훈 (부산대학교 의과대학 내과학교실) ;
  • 이성준 (부산대학교 의과대학 내과학교실) ;
  • 이문원 (부산대학교 의과대학 내과학교실) ;
  • 한성용 (부산대학교 의과대학 내과학교실)
  • In Sub Han (Department of Internal Medicine, Pusan National University Hospital, Pusan National University School of Medicine) ;
  • Geun Am Song (Department of Internal Medicine, Pusan National University Hospital, Pusan National University School of Medicine) ;
  • Kwang Ha Kim (Department of Internal Medicine, Pusan National University Hospital, Pusan National University School of Medicine) ;
  • Bong Eun Lee (Department of Internal Medicine, Pusan National University Hospital, Pusan National University School of Medicine) ;
  • Dong Hoon Baek (Department of Internal Medicine, Pusan National University Hospital, Pusan National University School of Medicine) ;
  • Seong Jun Lee (Department of Internal Medicine, Pusan National University Hospital, Pusan National University School of Medicine) ;
  • Moon Won Lee (Department of Internal Medicine, Pusan National University Hospital, Pusan National University School of Medicine) ;
  • Sung Yong Han (Department of Internal Medicine, Pusan National University Hospital, Pusan National University School of Medicine)
  • 투고 : 2016.06.03
  • 심사 : 2016.06.16
  • 발행 : 2016.06.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

복막 가성점액종은 표준치료인 종양감축수술과 함께 복강 내 고온열 항암요법과의 병합치료로 생존율의 향상을 기대할 수 있다. 재발성 병변에 대해서는 추가적인 종양감축 수술이 권고되고 있지만, 치료시기에 따른 이환율과 사망률의 차이가 있어 조기발견이 중요하다. 수술 전 혈청 종양표지자 검사의 수치 이상 여부에 따른 재발과 생존율의 상관관계를 알아보고자 하는 연구들은 있지만, 추적관찰 중 수치 이상에 따른 재발여부에 관한 연구는 거의 없다. 저자들은 CSR과 HIPEC, 그리고 전신 항암화학요법을 시행받은 환자에서 CEA의 수치 상승이 질병의 재발과 상관관계가 있었음을 경험하였기에 보고하는 바이다.

Pseudomyxoma peritonei (PMP) is a rare clinical syndrome characterized by profuse jelatinous materials in the abdominal cavity and pelvis with mucinous implants on the peritoneal surface. There are some studies for serum tumor markers, including carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9) and carbohydrate antigen 125 (CA125), to assess the risk of recurrence following cytoreductive surgery and intraperitoneal chemotherapy. However, rare cases were reported about recurrence with increasing serum CEA levels. Herein, we report a case of recurrence of PMP according to serially elevated serum CEA.

키워드

과제정보

This work was supported by a 2-Year Research Grant of Pusan National University.

참고문헌

  1. Smeenk RM, van Velthuysen ML, Verwaal VJ, et al. Appendiceal neoplasms and pseudomyxoma peritonei: a population based study. Eur J Surg Oncol 2008;34:196-201.
  2. Canbay E, Ishibashi H, Sako S, et al. Preoperative carcinoembryonic antigen level predicts prognosis in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Surg 2013;37:1271-1276.
  3. Van Ruth S, Hart AA, Bonfrer JM, et al. Prognostic value of baseline and serial carcinoembryonic antigen and carbohydrate antigen 19.9 measurements in patients with pseudomyxoma peritonei treated with cytoreduction and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol 2002;9:961-967.
  4. Ronnett BM, Shmookler BM, Sugarbaker PH, et al. Pseudomyxoma peritonei: new concepts in diagnosis, origin, nomenclature, and relationship to mucinous borderline (low malignant potential) tumors of the ovary. Anat Pathol 1997;2:197-226.
  5. Sugarbaker PH, Ronnett BM, Archer A, et al. Pseudomyxoma peritonei syndrome. Adv Surg 1996;30:233-238.
  6. Fernandez RN, Daly JM. Pseudomyxoma peritonei. Arch Surg 1980;115:409-14.
  7. Sulkin TV, O'Neill H, Amin AI, et al. CT in pseudomyxoma peritonei: a review of 17 cases. Clin Radiol 2002;57:608-613.
  8. Hinson FL, Ambrose NS. Pseudomyxoma peritonei. Br J Surg 1998;85:1332-1339.
  9. Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 2004;22:3284-3292.
  10. Moran B, Cecil T, Chandrakumaran K, et al. The results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1200 patients with peritoneal malignancy. Colorectal Dis 2015;17:772-778.
  11. Alexander-Sefre F, Chandrakumaran K, Banerjee S, et al. Elevated tumour markers prior to complete tumour removal in patients with pseudomyxoma peritonei predict early recurrence. Colorectal Dis 2005;7:382-386.
  12. Taflampas P, Dayal S, Chandrakumaran K, et al. Pre-operative tumour marker status predicts recurrence and survival after complete cytoreduction and hyperthermic intraperitoneal chemotherapy for appendiceal Pseudomyxoma Peritonei: Analysis of 519 patients. Eur J Surg Oncol 2014;40:515-520.